Clinical correlates of enlarged prostate size in subjects with sexual dysfunction

Asian Journal of Andrology

Volumn 16, Issue 5, 2014, Pages 767-773

  Corona, Giovanni ^a   Gacci, Mauro ^b   Maseroli, Elisa ^b   Rastrelli, Giulia ^b   Vignozzi, Linda ^b   Sforza, Alessandra ^a   Forti, Gianni ^b   Mannucci, Edoardo ^c   Maggi, Mario ^b  

^a BELLARIA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

benign prostatic hyperplasia; metabolic syndrome enlarged prostate size; testosterone

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLESTEROL; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; DEPRESSION; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HETEROSEXUAL MALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREMATURE EJACULATION; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATE SIZE; PROSTATE VOLUME; RETROSPECTIVE STUDY; RISK FACTOR; SEXUAL DYSFUNCTION; VARICOCELE; AGED; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPOTENCE, VASCULOGENIC; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PROSTATE; PROSTATIC HYPERPLASIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

ADULT; AGED; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIGITAL RECTAL EXAMINATION; ERECTILE DYSFUNCTION; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPOTENCE, VASCULOGENIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ORGAN SIZE; PREMATURE EJACULATION; PROSTATE; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VARICOCELE;

EID: 84907010262     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.126382     Document Type: Article

References (67)

1. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33: 475-88.
2. Kirby M, Chapple C, Jackson G, Eardley I, Edwards D, et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract 2013; 67: 606-18.
3. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, et al. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur Urol 2013; 64: 118-40.
4. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809-25.
5. Corona G, Mondaini N, Ungar A, Razzoli E, Rossi A, et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sex Med 2011; 8: 3418-32.
6. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism (s) of action. Neurourol Urodyn 2011; 30: 292-301.
7. Hatzichristou D, Rosen RC, Derogatis LR, Low WY, Meuleman EJ, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010; 7 (1 Pt 2): 337-48.
8. Ghanem HM, Salonia A, Martin-Morales A. SOP: physical examination and laboratory testing for men with erectile dysfunction. J Sex Med 2013; 10: 108-10.
9. Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med 2013; 10: 2518-28.
10. Bancroft J, Carnes L, Janssen E, Goodrich D, Long JS. Erectile and ejaculatory problems in gay and heterosexual men. Arch Sex Behav 2005; 34: 285-97.
11. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9.
12. Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 2007; 51: 1645-52.
13. Chung BH, Hong SJ, Cho JS, Seong DH. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 2006; 97: 742-6.
14. Mochtar CA, Kiemeney LA, van Riemsdijk MM, Barnett GS, Laguna MP, et al. Prostate specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44: 695-700.
15. Althof SE, Rosen RC, Perelman MA, Rubio-Aurioles E. Standard Operating Procedures for Taking a Sexual History. J Sex Med 2013; 10: 26-35.
16. Petrone L, Mannucci E, Corona G, Bartolini M, Forti G, et al. Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 2003; 15: 210-20.
17. Corona G, Petrone L, Mannucci E, Magini A, Lotti F, et al. Assessment of the relational factor in male patients consulting for sexual dysfunction: the concept of couple sexual dysfunction. J Androl 2006; 27: 795-801.
18. Boddi V, Corona G, Fisher AD, Mannucci E, Ricca V, et al. It Takes Two to Tango": the Relational Domain in a Cohort of Subjects with Erectile Dysfunction (ED). J Sex Med 2012; 9: 3126-36.
19. Corona G, Mannucci E, Lotti F, Boddi V, Jannini EA, et al. Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. J Sex Med 2009; 6: 2591-600.
20. Corona G, Ricca V, Bandini E, Rastrelli G, Casale H, et al. SIEDY Scale 3, a New Instrument to Detect Psychological Component in Subjects with Erectile Dysfunction. J Sex Med 2012; 9: 2017-26.
21. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, et al. Psycho-biological correlates of free-floating anxiety symptoms in male patients with sexual dysfunctions. J Androl 2006; 27: 86-93.
22. Corona G, Rastrelli G, Ricca V, Jannini EA, Vignozzi L, et al. Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction. J Sex Med 2013; 10: 1074-89.
23. Corona G, Jannini EA, Vignozzi L, Rastrelli G, Maggi M. The hormonal control of ejaculation. Nat Rev Urol 2012; 9: 508-19.
24. Corona G, Jannini EA, Lotti F, Boddi V, De Vita G, et al. Premature and delayed ejaculation: two ends of a single continuum influenced by hormonal milieu. Int J Androl 2011; 34: 41-8.
25. Corona G, Mannucci E, Petrone L, Fisher AD, Balercia G, et al. Psychobiological correlates of delayed ejaculation in male patients with sexual dysfunctions. J Androl 2006; 27: 453-8.
26. Crown S, Crisp AH. A short clinical diagnostic self-rating scale for psychoneurotic patients. The Middlesex Hospital Questionnaire (M.H.Q.). Br J Psychiatry 1966; 112: 917-23.
27. Corona G, Mannucci E, Ricca V, Lotti F, Boddi V, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009; 32: 720-8.
28. Corona G, Ricca V, Bandini E, Mannucci E, Petrone L, et al. Association between psychiatric symptoms and erectile dysfunction. J Sex Med 2007; 5: 458-68.
29. McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol 2005; 161: 483-93.
30. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
31. Corona G, Fagioli G, Mannucci E, Romeo A, Rossi M, et al. Penile doppler ultrasound in patients with erectile dysfunction (ED): role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med 2008; 5: 2623-34.
32. Sikka SC, Hellstrom WJ, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med 2013; 10: 120-9.
33. Hatzichristou D, Rosen R, Derogatis L, Low WY, Meuleman E, et al. Clinical evaluation and symptom scales in men and women with sexual dysfunction. In: Montorsi, Basson Adaikan, Becher, Clayton, Giuliano, et al. editors. Sexual Medicine: sexual dysfunctions in men and women. The 3rd International Consultation on Sexual Medicine. Health Publication Ltd: Paris, France; 2010. p. 229-80.
34. Rastrelli G, Corona G, Lotti F, Aversa A, Bartolini M, et al. Flaccid penile acceleration as a marker of cardiovascular risk in men without classical risk factors. J Sex Med 2014; 11: 173-86.
35. Lotti F, Corona G, Mancini M, Filimberti E, Degli Innocenti S, et al. Ultrasonographic and clinical correlates of seminal plasma interleukin-8 levels in patients attending an andrology clinic for infertility. Int J Androl 2011; 34 (6 Pt 1): 600-13.
36. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al., EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
37. Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, et al. Benign prostatic hyperplasia a new metabolic disease of the aging male. Int J Endocrinology 2014.
38. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol 2012; 212: 71-84.
39. Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 2013; 16: 101-6.
40. Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008; 101: 313-8.
41. Li PJ, Zhang XH, Guo LJ, Na YQ. Correlation of benign prostatic hyperplasia with hyperlipemia. Zhonghua Wai Ke Za Zhi 2005; 43: 387-9.
42. Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013; 73: 789-800.
43. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009; 30: 10-22.
44. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, et al. Hypogonadism and Metabolic Syndrome. J Endocrinol Invest 2011; 34: 557-67
45. Kupelian V, Shabsigh R, Araujo AB, O'Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006; 176: 222-6.
46. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-49.
47. Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 2005; 96: 1073-8.
48. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006; 98: 1038-42.
49. Pinggera GM, Mitterberger M, Steiner E, Pallwein L, Frauscher F, et al. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: Assessment using colour Doppler ultrasonography. BJU Int 2008; 102: 470-20.
50. Park DS, Oh JJ, Hong JY, Hong YK, Choi DK, et al. Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study. Asian J Androl 2013; 15: 249-53.
51. Corona G, Mannucci E, Lotti F, Fisher AD, Bandini E, et al. Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with ED. J Sex Med 2009; 6: 285-93.
52. Lotti F, Corona G, Mancini M, Biagini C, Colpi GM, et al. The association between varicocele, premature ejaculation and prostatitis symptoms: possible mechanisms. J Sex Med 2009; 6: 2878-87.
53. Gat Y, Gornish M, Heiblum M, Joshua S. Reversal of benign prostate hyperplasia by selective occlusion of impaired venous drainage in the male reproductive system: Novel mechanism, new treatment. Andrologia 2008; 40: 273-81.
54. Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, et al. Prevalence of chronic prostatitis in men with premature ejaculation. Urology 2001; 58: 198-202.
55. Corona G, Wu FC, Forti G, Lee DM, O'Connor DB, et al. Thyroid hormones and male sexual function. Int J Androl 2012; 35: 668-79.
56. Carani C, Isidori AM, Granata A, Carosa E, Maggi M, et al. Multicenter study on the prevalence of sexual symptoms in male hypo-and hyperthyroid patients. J Clin Endocrinol Metab 2005; 90: 6472-9
57. Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, et al. PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013; 73: 1391-402.
58. Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate 2013; 73: 428-41.
59. Jannini EA, McMahon C, Chen J, Aversa A, Perelman M. The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation. J Sex Med 2011; 8: 2135-43.
60. Jannini EA, Maggi M, Lenzi A. Evaluation of premature ejaculation. J Sex Med 2011; 8 Suppl 4: 328-34.
61. Althof SE. Quality of life and erectile dysfunction. Urology 2002; 59: 803-10.
62. Mitropoulos D, Anastasiou I, Giannopoulou C, Nikolopoulos P, Alamanis C, et al. Symptomatic benign prostate hyperplasia: impact on partner's quality of life. Eur Urol 2002; 41: 240-5.
63. Yanoshak SJ, Roehrborn CG, Girman CJ, Jaffe JS, Ginsberg PC, et al. Use of a prostate model to assist in training for digital rectal examination. Urology. 2000; 55: 690-3.
64. Roehrborn CG, Sech S, Montoya J, Rhodes T, Girman CJ. Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology 2001; 57: 1087-92.
65. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with -blockers for lower uninary tract symtoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994-1003.
66. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011; 8: 2746-60.
67. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010; 7 (1 Pt 1): 107-20.